SEC Form 4 · accession 0001209191-16-089929
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yuchun Lee
Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 4, 2016 | M | 1,333 | $57.27 | A | 2,166 | D | |
| Common StockF2,F3 | Jan 4, 2016 | S | 925 | $122.07 | D | 1,241 | D | |
| Common StockF2,F4 | Jan 4, 2016 | S | 200 | $122.87 | D | 1,041 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $57.27 | Jan 4, 2016 | M | 1,333 | D | — | Sep 13, 2022 | Common Stock | 1,333 | 23,334 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- F2Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $122.07 (range $121.51 to $122.48).
- F4Open market sales reported on this line occurred at a weighted average price of $122.87 (range $122.71 to $123.03).
- F5The option vests in 16 quarterly installments from 09/14/2012.